TG Therapeutics Statistics

Total Valuation

TG Therapeutics has a market cap or net worth of EUR 6.08 billion. The enterprise value is 6.03 billion.

Market Cap	6.08B
Enterprise Value	6.03B

Important Dates

The next estimated earnings date is Monday, May 5, 2025.

Earnings Date	May 5, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	+7.96%
Shares Change (QoQ)	-0.29%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	148.20M

Valuation Ratios

The trailing PE ratio is 269.32.

PE Ratio	269.32
Forward PE	n/a
PS Ratio	19.14
PB Ratio	28.32
P/TBV Ratio	28.32
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 154.43, with an EV/FCF ratio of -153.98.

EV / Earnings	267.11
EV / Sales	20.79
EV / EBITDA	154.43
EV / EBIT	163.15
EV / FCF	-153.98

Financial Position

The company has a current ratio of 6.25, with a Debt / Equity ratio of 1.14.

Current Ratio	6.25
Quick Ratio	4.85
Debt / Equity	1.14
Debt / EBITDA	5.74
Debt / FCF	-6.27
Interest Coverage	1.75

Financial Efficiency

Return on equity (ROE) is 12.21% and return on invested capital (ROIC) is 7.00%.

Return on Equity (ROE)	12.21%
Return on Assets (ROA)	5.78%
Return on Invested Capital (ROIC)	7.00%
Return on Capital Employed (ROCE)	8.61%
Revenue Per Employee	940,192
Profits Per Employee	66,821
Employee Count	338
Asset Turnover	0.73
Inventory Turnover	0.51

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

Beta (5Y)	n/a
52-Week Price Change	n/a
50-Day Moving Average	n/a
200-Day Moving Average	n/a
Relative Strength Index (RSI)	n/a
Average Volume (20 Days)	n/a

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	8.61

Income Statement

In the last 12 months, TG Therapeutics had revenue of EUR 317.78 million and earned 22.59 million in profits. Earnings per share was 0.14.

Revenue	317.78M
Gross Profit	280.61M
Operating Income	40.50M
Pretax Income	24.72M
Net Income	22.59M
EBITDA	40.56M
EBIT	40.50M
Earnings Per Share (EPS)	0.14

Full Income Statement

Balance Sheet

The company has 300.39 million in cash and 245.71 million in debt, giving a net cash position of 54.69 million.

Cash & Cash Equivalents	300.39M
Total Debt	245.71M
Net Cash	54.69M
Net Cash Per Share	n/a
Equity (Book Value)	214.78M
Book Value Per Share	1.49
Working Capital	459.46M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -39.14 million and capital expenditures -43,466, giving a free cash flow of -39.18 million.

Operating Cash Flow	-39.14M
Capital Expenditures	-43,466
Free Cash Flow	-39.18M
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 88.30%, with operating and profit margins of 12.74% and 7.11%.

Gross Margin	88.30%
Operating Margin	12.74%
Pretax Margin	7.78%
Profit Margin	7.11%
EBITDA Margin	12.76%
EBIT Margin	12.74%
FCF Margin	n/a

Dividends & Yields

TG Therapeutics does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-7.96%
Shareholder Yield	-7.96%
Earnings Yield	0.37%
FCF Yield	-0.64%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

TG Therapeutics has an Altman Z-Score of 3.11.

Altman Z-Score	3.11
Piotroski F-Score	n/a